Sort by
Refine Your Search
-
infrastructure to make pathogen sequencing more accessible, interpretable, and equitable? This software developer position offers a unique opportunity to work at the intersection of two world-leading efforts
-
applies state of the art technologies to sequence the genomes and transcriptomes of farm animals with long and short reads, and applies bioinformatics and statistical genomics approaches to characterize
-
and interpretation of large-scale datasets, in particular next generation sequencing (NGS) data. The team covers raw data processing, high-performance computing, statistical evaluation, interpretation
-
stakeholders, ensuring alignment and operational execution of Biogen’s clinical trials. This individual represents Biogen at in-country scientific, regulatory, and patient organization meetings while providing
-
The Animal Genomics group at the Institute of Agricultural Sciences at ETH Zurich investigates DNA variation in individual genomes and at the population scale. We apply long read sequencing
-
of Directors and the Steering Committee, you will help plan and evaluate projects, monitor scientific progress and ensure alignment with the consortium's goals. You will lead the preparation of key documents
-
this vision into a comprehensive, measurable strategic plan. Program & Project Management: Orchestrate the implementation phases (foundations & traction, integration & consolidation, scaling & multiplication
-
, Microtechnologies, Bioengineering, High-throughput imaging, CRISPR-gene editing, Biobanking, Automation, Applied translation support Core facilities: Fluorescent microscopy, Genomics and high-throughput sequencing
-
infrastructure, including robotic high-throughput cultivation and Next-Generation Sequencing, and is closely integrated into international networks and projects. The University of Bern seeks an outstanding
-
diverse stakeholder community. This role requires exceptional scientific expertise, strong organizational skills, and the ability to drive the delivery of our screening objectives in alignment with Roche’s